Bausch + Lomb Reports 5% Revenue Growth to $1.278 Billion in Q2 2025

Bausch + Lomb Corporation reported its financial results for the second quarter of 2025, revealing a revenue of $1.278 billion, a 5% increase from $1.216 billion in the same period last year. For the first half of 2025, total revenues reached $2.415 billion, up from $2.315 billion in the prior year, marking a 4% growth. The increase in revenue was primarily driven by higher volumes across its Vision Care and Pharmaceuticals segments, as well as favorable foreign currency impacts. However, the company also faced challenges, including a decrease in net realized pricing, particularly in its Pharmaceuticals segment, which contributed to a net loss of $62 million for the quarter, an improvement from a loss of $151 million in the same quarter of 2024.

In terms of operational performance, the Vision Care segment generated $753 million in revenue for the second quarter, an 8% increase from $697 million in the previous year, largely due to strong sales in its dry eye portfolio and contact lenses. The Pharmaceuticals segment, however, saw a slight decline in revenue, totaling $309 million, down from $310 million, attributed to pricing pressures and declines in the U.S. generics business. The Surgical segment reported a revenue increase to $216 million from $209 million, despite the impact of a voluntary recall of certain enVista intraocular lenses (IOLs).

Bausch + Lomb has been active in strategic acquisitions, including the purchase of Whitecap Biosciences in January 2025, which is expected to enhance its clinical-stage pipeline. The company also acquired Elios Vision and Trukera Medical in late 2024, further expanding its product offerings in the glaucoma and dry eye markets. These acquisitions are part of Bausch + Lomb's strategy to leverage its commercial footprint and address unmet needs in the eye health market.

The company’s financial position showed total assets of $13.832 billion as of June 30, 2025, with total liabilities of $7.324 billion, resulting in shareholders' equity of $6.508 billion. Bausch + Lomb's cash and cash equivalents decreased to $266 million from $305 million at the end of 2024. The company reported a significant increase in interest expense, totaling $128 million for the quarter, up from $102 million, primarily due to refinancing activities. Looking ahead, Bausch + Lomb anticipates continued revenue growth driven by its product pipeline and strategic initiatives, although it remains cautious about potential impacts from macroeconomic factors and ongoing geopolitical tensions.